A Phase 3, Multicenter Randomized Open label Active controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator assigned treatment in transplant recipients with Cytomegalovirus Infections that are Refractory or Resis

Grants and Contracts Details

StatusFinished
Effective start/end date7/18/17 → 6/14/21

Funding

  • Shire Human Genetic Therapies Incorporated: $114,911.00